Atossa Therapeutics announces five abstracts on Z-endoxifen

Atossa Therapeutics (ATOS) announced that five abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium, SABCS, taking place December 10-13, 2024, in San Antonio, Texas. The presentations will showcase significant findings from various studies evaluating the use of (Z)-endoxifen in breast cancer prevention and treatment, including phase 2 trials and innovative combination therapy research. “We are excited to present a comprehensive body of research on (Z)-endoxifen at SABCS 2024,” said Dr. Steven Quay, President and Chief Executive Officer of Atossa Therapeutics. “These presentations highlight our commitment to advancing breast cancer treatment and prevention, showcasing the potential of (Z)-endoxifen to bring meaningful treatment options to patients with breast cancer.”